NeuroSense Therapeutics H1 EPS $(2.10) up From $(3.70) YoY
NeuroSense Therapeutics (NASDAQ:NRSN) reported quarterly losses of $(2.10). This is a 43.24 percent increase over losses of $(3.70) per share from the same period last year.
Stocks · News reference
NeuroSense Announces Redesigned Development Plan For PrimeC In Amyotrophic Lateral Sclerosis, Structured To Reach Potential Path For Regulatory Submission And Faster Approval
Three-part program - AI-enabled characterization of PrimeC's formulation advantage, an active-comparator trial against edaravone, and a streamlined pivotal pathway - is designed to strengthen PrimeC's
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Trading Halt: Halted at 7:50:00 p.m. ET - Trading Halt: Halt News Pending
NeuroSense Therapeutics Announces 1-For-20 Reverse Stock Split, Effective Sept. 14
SEC. https://www.sec.gov/Archives/edgar/data/1875091/000121390026098414/ea0304823-6k_neurosense.htm
This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday
Analysts initiated coverage with Buy ratings on SpaceX, Securitize ; Overweight on Londian Wason.